Bagdas Deniz, Yucel-Ozboluk Hasret, Orhan Fulya, Kanat Ozkan, Isbil-Buyukcoskun Naciye, Gurun Mine S
aExperimental Animals Breeding and Research Center Departments of bPharmacology cPhysiology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Neuroreport. 2013 Dec 4;24(17):941-6. doi: 10.1097/WNR.0000000000000009.
Recent studies have demonstrated that arginine vasopressin (AVP) plays a crucial role in pain modulation. In addition, our previous studies have proven that centrally administered cytidine-5'-diphosphate-choline (CDP-choline; citicoline) elicits an analgesic effect in different pain models in rats. Given that CDP-choline enhances central and peripheral vasopressin levels, the present study was designed to investigate the role of central AVP receptors in the analgesic effect of CDP-choline in acute and chronic constriction injury-induced neuropathic pain models. For this purpose, rats were pretreated intracerebroventricularly with the AVP V1 or AVP V2 receptor antagonist 15 min before intracerebroventricular injection of CDP-choline or saline, and pain threshold was determined using the Randall-Selitto test. AVP V1 and AVP V2 receptor antagonist blocked the CDP-choline-induced analgesic effect either in acute or neuropathic models of pain in rats. These results suggest, for the first time, that central AVP receptors are involved in the CDP-choline-elicited analgesic effect.
